BioSpace News Archive

The approval follows the U.S. Food and Drug Administration (FDA) providing clearance to proceed with the Company’s Investigational New Drug (IND) application to commence this trial, as announced by the Company on August 24th, 2021.

Inceptor Bio (“Inceptor”), today announced an agreement with Arranta Bio (“Arranta”) for the acquisition of a 29,000 ft2 process development and GMP clinical manufacturing facility and the transfer of a core operating team to establish cell therapy processes and clinical supply for Inceptor Bio’s planned oncology clinical trials.

Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today the launch of two innovative Air-Dryable™ qPCR Mixes that enable direct detection of DNA or RNA/DNA from urine samples.

Eurofins Eaton Analytical is prepared for UCMR5 testing in advance of anticipated rule release.

China and the USA predicted to lead innovation by 2030 in an age of mass personalized therapeutics, cobots, AI, and automation delivering process improvements.

Natural Language Processing (NLP) firm, Melax Tech, announced today that it is moving forward with a text extraction project in conjunction with Houston’s Baylor College of Medicine.

Deciduous Therapeutics announced today the appointment of an independent board member, additional Scientific Advisory Board members, and company advisors.

Aston Sci., a portfolio model biopharmaceutical company, announced that the study results of its therapeutic cancer vaccine pipelines, AST-301 and AST-021p, will be presented at the Society for Immunotherapy of Cancer(SITC) in November.

Steven Lehrer’s 40 years of Biotech experience enhances the board of advisors with expertise in pharmaceutical, biopharmaceutical, and biosimilar R&D.

Marvel has identified a series of compounds inspired by known psychedelic molecules, that appear to be active as anti-depressants in pre-clinical testing.